Risk ranking method and device

Abstract

The embodiment of the present application provides a risk ranking method, which is applied in a drug vigilance system. The ranking method includes: obtaining the level information of the user who currently accesses the drug vigilance system, and determining the risks of multiple projects in the drug vigilance system, wherein there is a preset mapping relationship between users of different levels in the drug vigilance system and different project risk rankings; based on the level information and the preset mapping relationship, the risks of multiple projects are ranked to obtain the project risk ranking results; and the project risk ranking results are displayed to the user. The risk ranking method and device of the present application can obtain the level information of the user of the drug vigilance system, and perform corresponding risk ranking according to different level information, so that users of different levels can preferentially see the project risks that are suitable for them to handle.

Description

Technical Field

[0001] The present application relates to the field of pharmacovigilance systems, and more specifically, to a risk ranking method, device, computer-readable storage medium, and electronic device. Background Art

[0002] The establishment of a pharmacovigilance system places high demands on the professional capabilities of the users of the pharmacovigilance system. Each user member needs to undergo training and combine standard operating procedures (SOP) to clarify their respective responsibilities.

[0003] The existing risk ranking method in the pharmacovigilance system is to sort according to the importance of the risks. It is difficult for pharmacovigilance users to quickly find project risks that are suitable for them to handle, which reduces the efficiency of the use of the pharmacovigilance system. Summary of the invention

[0004] In view of this, embodiments of the present application provide a risk ranking method, device, computer-readable storage medium, and electronic device, which enable users of different levels in a drug vigilance system to preferentially see project risks that are suitable for them to handle.

[0005] In a first aspect, an embodiment of the present application provides a risk ranking method, which is applied in a drug vigilance system. The ranking method includes: obtaining the level information of the user who currently accesses the drug vigilance system, and determining the risks of multiple projects in the drug vigilance system, wherein there is a preset mapping relationship between users of different levels in the drug vigilance system and different project risk rankings; based on the level information and the preset mapping relationship, ranking the risks of multiple projects to obtain a project risk ranking result; and displaying the project risk ranking result to the user.

[0006] In certain embodiments of the present application, before obtaining the level information of the user currently accessing the pharmacovigilance system, it also includes: receiving a risk ranking request input by the user in the pharmacovigilance system, the risk ranking request including the user's identification information, which is used to request the pharmacovigilance system to rank the risks of multiple projects based on the level information and a preset mapping relationship.

[0007] In certain embodiments of the present application, the level information of a user of a pharmacovigilance system is obtained, and the risks of multiple items of the pharmacovigilance system are determined, including: when a user accesses a risk display page in the pharmacovigilance system, the level information of the user currently accessing the pharmacovigilance system is obtained, and the risks of multiple items of the pharmacovigilance system are determined.

[0008] In certain embodiments of the present application, a preset mapping relationship between users of different levels and different project risk rankings is determined according to pharmacovigilance regulations, wherein the pharmacovigilance system is built according to the standard operating procedure documents of pharmacovigilance.

[0009] In certain embodiments of the present application, obtaining the level information of a user currently accessing the pharmacovigilance system includes: obtaining an identity identifier of the user currently accessing the pharmacovigilance system; and determining the level information of the user according to the identity identifier.

[0010] In certain embodiments of the present application, determining the risks of multiple items of a drug vigilance system includes: determining the risks of the multiple items based on adverse reaction information, wherein the adverse reaction information includes one or more of a monthly suspected serious reporting amount and a monthly serious adverse event reporting amount.

[0011] In certain embodiments of the present application, determining the risks of multiple projects based on adverse reaction information includes: weighting the adverse reaction information to obtain a weighted adverse reaction information index; and determining the risks of multiple projects based on the adverse reaction information index.

[0012] In the second aspect, an embodiment of the present application provides a risk ranking device, which is applied in a drug vigilance system, and the ranking device includes: an acquisition module, which is used to obtain the level information of the user who currently accesses the drug vigilance system, and determine the risks of multiple projects in the drug vigilance system, wherein there is a preset mapping relationship between users of different levels in the drug vigilance system and different project risk rankings; a ranking module, which is used to sort the risks of multiple projects based on the level information and the preset mapping relationship, and obtain a project risk ranking result; a display module, which is used to display the project risk ranking result to the user.

[0013] In a third aspect, an embodiment of the present application provides a computer-readable storage medium, wherein the storage medium stores a computer program, and the computer program is used to execute the risk ranking method of the first aspect above.

[0014] In a fourth aspect, an embodiment of the present application provides an electronic device, comprising: a processor; and a memory for storing processor executable instructions, wherein the processor is used to execute the risk ranking method of the first aspect above.

[0015] The risk ranking method and device of the present application can obtain the level information of users of the drug vigilance system, and perform corresponding risk ranking according to different level information, so that users of different levels can preferentially see the project risks that are suitable for their own processing, thereby improving the efficiency of risk elimination of the drug vigilance system. BRIEF DESCRIPTION OF THE DRAWINGS

[0016] Figure 1A flowchart of a risk ranking method provided in accordance with an embodiment of the present application.

[0017] Figure 2 A flowchart of a risk ranking method provided in another embodiment of the present application.

[0018] Figure 3 A schematic diagram of the structure of a risk ranking device provided in one embodiment of the present application.

[0019] Figure 4 A block diagram of an electronic device for executing a risk ranking method provided in accordance with an exemplary embodiment of the present application. DETAILED DESCRIPTION

[0020] The embodiments of the present application will be described in more detail below with reference to the accompanying drawings. Although certain embodiments of the present application are shown in the accompanying drawings, it should be understood that the present application can be implemented in various forms and should not be construed as being limited to the embodiments described herein. Instead, these embodiments are provided to provide a more thorough and complete understanding of the present application. It should be understood that the drawings and embodiments of the present application are only for exemplary purposes and are not intended to limit the scope of protection of the present application.

[0021] The term "including" and its variations used in this application are open inclusions, i.e., "including but not limited to". The term "according to" means "at least in part according to". The term "one embodiment" means "at least one embodiment"; the term "another embodiment" means "at least one additional embodiment". The relevant definitions of other terms will be given in the following description.

[0022] Pharmacovigilance, also known as drug safety, is a broad term that includes the collection, analysis, monitoring and prevention of adverse reactions to medicines and treatments.

[0023] The embodiments of the present application can be used in a pharmacovigilance system. The purpose of a pharmacovigilance system is to establish and continuously develop a powerful and innovative system that is responsible for acquiring and storing a large amount of safety data. These data are usually organized by professional users (or members) of the pharmacovigilance system, and only relevant users of the pharmacovigilance system who have obtained permission can access them. As a very challenging and important part of drug safety, the pharmacovigilance system needs to be continuously improved and kept in compliance with the regulations and requirements of the commercial and health departments.

[0024] The establishment of a pharmacovigilance system requires high professional capabilities from the members of the pharmacovigilance system. Each member needs to undergo training and combine standard operating procedures (SOP) to clarify their respective responsibilities. The existing risk ranking method in the pharmacovigilance system is to rank according to the importance of risks and produce a single ranking result, that is, each level of users sees the same ranking result. However, users at different levels may focus on different risks. For example, users at important levels may focus on high-risk projects, while users at lower levels may pay more attention to projects with lower risks. This makes it difficult for users at different levels to quickly find project risks that are suitable for them to handle among many project risks, reducing the efficiency of the use of the pharmacovigilance system.

[0025] In order to solve the above problems, the present application provides a risk ranking method and device, which can enable users of different levels in the drug vigilance system to preferentially see project risks that are suitable for their own processing.

[0026] Figure 1 The flowchart of the risk ranking method provided by one embodiment of the present invention is schematically shown. Figure 1 The method described is performed by a computing device (e.g., a server), but the embodiments of the present application are not limited thereto. The server may be a single server, or may be composed of a plurality of servers, or may be a virtualization platform, or may be a cloud computing service center, and the embodiments of the present application are not limited thereto. Figure 1 As shown, the method includes the following contents.

[0027] S110: Obtaining level information of a user currently accessing the pharmacovigilance system, and determining risks of multiple projects of the pharmacovigilance system, wherein a preset mapping relationship exists between users of different levels and different project risk rankings in the pharmacovigilance system.

[0028] Users (or members) of the pharmacovigilance system often have different levels, for example, the levels can be divided into junior, senior and experienced. The level can be determined according to the user's qualifications. For example, senior-level users are considered experts in professional fields, and their expertise is used in a wider range of business, including understanding, planning and advising on the regulations and requirements that companies must comply with in the corresponding countries or organizations (such as the European Union). Senior and junior can be divided according to the number of years of work. For example, users who have worked in the pharmacovigilance system for less than three years are junior, and users who have worked for more than three years are senior.

[0029] In the pharmacovigilance system, the risks of different projects will be different, some projects have higher risks, and some projects have lower risks. In the process of studying the pharmacovigilance system, the applicant found that in the process of users of the pharmacovigilance system dealing with project risks, senior users tend to focus on projects with higher risks, while junior users and advanced users focus on projects with slightly lower risks, that is, users at different levels have different levels of attention to the risks of different projects. The risk sorting method in the existing pharmacovigilance system is to sort according to the risk level, and users at all levels see the same sorting result, which makes it difficult for users of the pharmacovigilance system to quickly find project risks that are suitable for them to handle, reducing the efficiency of the use of the pharmacovigilance system. Therefore, in the risk sorting method of the present application, there is a preset mapping relationship between users of different levels and different project risk sorting. For example, for senior users, the sorting results give priority to displaying projects with higher risks, and for junior users, the sorting results give priority to displaying projects with lower risks.

[0030] S120: Sort the risks of multiple projects based on the level information and the preset mapping relationship to obtain a project risk sorting result.

[0031] After obtaining the level information of the current user and determining the risks of multiple projects, the risk sorting method of the present application sorts the risks of multiple projects based on the level information and the preset mapping relationship, and obtains the project risk sorting results, and obtains new project risk sorting results, that is, the project risk sorting results of users of different levels are different. For example, in the sorting results of senior users, projects with higher risks are displayed first, and in the sorting results of junior users, projects with lower risks are displayed first.

[0032] S130: Display the project risk ranking result to the user.

[0033] After obtaining the project risk ranking results, the project risk ranking results can be displayed or pushed to the user or user interface, so that the user can immediately see the ranking results and find the project risks suitable for the user to handle in the ranking results.

[0034] The risk ranking method of the present application enables users of different levels in the drug vigilance system to preferentially see project risks that are suitable for them to handle, thereby improving the work efficiency of users.

[0035] In one embodiment of the present application, before obtaining the level information of the user currently accessing the drug vigilance system, it also includes: receiving a risk ranking request input by the user in the drug vigilance system, the risk ranking request including the user's identification information, which is used to request the drug vigilance system to rank the risks of multiple projects based on the level information and a preset mapping relationship.

[0036] Specifically, the pharmacovigilance system may also first receive a risk ranking request from a user, and then obtain the user's level information. The risk ranking request includes the user's identification information, and the identification information is used to request the pharmacovigilance system to rank the risks of multiple projects based on the level information and the preset mapping relationship. Therefore, the pharmacovigilance system can learn the level of the user who issued the risk ranking request based on the user's identification information, and make a ranking result for specific project risks based on its level and the preset mapping relationship.

[0037] In one embodiment of the present application, the level information of a user of a drug vigilance system is obtained, and the risks of multiple items of the drug vigilance system are determined, including: when a user accesses a risk display page in the drug vigilance system, the level information of the user currently accessing the drug vigilance system is obtained, and the risks of multiple items of the drug vigilance system are determined.

[0038] Specifically, when a user visits a risk display page, the user's level information can be obtained and the risks of multiple projects can be determined, so that when the user issues a risk ranking request, the drug vigilance system can quickly obtain the project risk ranking results based on the obtained level information and the risks of the determined projects.

[0039] Optionally, a risk ranking request may be automatically issued when a user visits the risk display page, and the pharmacovigilance system quickly obtains the project risk ranking result based on the acquired level information and the risks of the determined projects.

[0040] Since the purpose of users visiting the risk display page is usually to understand the risk situation of the project, directly displaying the project risk ranking results corresponding to the user's level when the user visits the risk display page is beneficial for the user to obtain the project risk ranking results conveniently and quickly, further improving the user's usage experience.

[0041] In one embodiment of the present application, a preset mapping relationship between users of different levels and different project risk rankings is determined according to pharmacovigilance regulations, wherein the pharmacovigilance system is built based on the standard operating procedure documents of pharmacovigilance.

[0042] The pharmacovigilance system may include multiple modules, and the multiple modules may include one or more of an organizational structure, a medical dictionary, information tools, literature resources, a list of regulations, procedural documents, product information, and project information. Pharmacovigilance regulations are one of the bases for building a pharmacovigilance system. Some regulations may have an impact on the risk ranking process. For example, the risk of a new drug can only be handled by users in a specific field or at a specific level. Therefore, the risk ranking method of this embodiment will read the pharmacovigilance regulations and determine that there is a preset mapping relationship between users of different levels and different project risk rankings according to the regulations.

[0043] The construction of the pharmacovigilance system can be carried out in a computer (e.g., a server). In the process of building the pharmacovigilance system, the standard operating procedure document of the pharmacovigilance can be obtained first, and then based on the name keywords and content keywords of multiple modules, the web page configuration data required for creating multiple modules can be obtained from the standard operating procedure document of the pharmacovigilance, and finally the web pages corresponding to the multiple functional modules are generated according to the web page configuration data to realize the online construction of the pharmacovigilance system. The way for the server to obtain the standard operating procedure document of the pharmacovigilance can be that the user (e.g., the pharmacovigilance user of the enterprise) directly uploads the standard operating procedure document of the pharmacovigilance through the user interface of the user terminal (e.g., a computer). The server can extract the web page configuration data required for building multiple modules from the standard operating procedure document of the pharmacovigilance according to the keywords included in the multiple modules in the pharmacovigilance system, wherein the keywords can be the name keywords or content keywords of multiple functional modules.

[0044] In an embodiment of the present application, obtaining the level information of a user currently accessing the pharmacovigilance system includes: obtaining an identity identifier of the user currently accessing the pharmacovigilance system; and determining the level information of the user according to the identity identifier.

[0045] Generally speaking, users in the pharmacovigilance system have their own identity identifiers, and the user's level information can be determined by obtaining the user's identity identifier. The identity identifiers of all users and the level information corresponding to each identity identifier can be stored in the pharmacovigilance system. When a user issues a risk ranking request, the pharmacovigilance system first reads the user's identity identifier, and then determines the user's level information based on the user's identity identifier to ensure the accuracy of the obtained level information.

[0046] In an embodiment of the present application, determining the risks of multiple items in the pharmacovigilance system includes: the pharmacovigilance system periodically detecting the risks of multiple items in the pharmacovigilance system.

[0047] Since pharmacovigilance regulations are updated in real time and some regulations may change, the pharmacovigilance system will periodically detect the risks of multiple projects to ensure compliance with pharmacovigilance regulations.

[0048] In one embodiment of the present application, determining the risks of multiple projects of a drug vigilance system includes: determining the risks of multiple projects based on enterprise information, the enterprise information including one or more of enterprise classification, enterprise operation type, enterprise business type, enterprise product type, enterprise annual income, total number of employees and enterprise address.

[0049] In the process of determining the risks of multiple projects, the risks of multiple projects can be determined based on enterprise information. Enterprise information can include enterprise classification E1, enterprise operation type E2, enterprise business type E3, enterprise product type E4, enterprise annual income E5, total number of employees E6 and enterprise address E7. Enterprise classification can be classified according to the holder and the sponsor. Enterprise operation type can include domestic enterprises, foreign-funded enterprises and joint ventures. Enterprise business type can be divided into enterprises whose main business is research and development, production and sales respectively. Enterprise product type can include innovative drugs and generic drugs.

[0050] After obtaining the enterprise information, we can first convert each enterprise information into a corresponding value, then perform weighted summation on the converted enterprise information to obtain the weighted enterprise information index EI, and then determine the risks of multiple projects based on the enterprise information index EI. The specific formula is as follows:

[0051]

[0052] In the formula, EI is the enterprise information index, i is the serial number of enterprise information, E i is the i-th enterprise information, w Ei is the weighting coefficient of the i-th enterprise information.

[0053] This embodiment uses enterprise information as a reference factor for the project risk of the pharmacovigilance system, so that the risk management of the pharmacovigilance system is combined with the enterprise, and can systematically, scientifically, objectively and comprehensively evaluate the risks of multiple projects.

[0054] In one embodiment of the present application, determining the risks of multiple items of a drug vigilance system includes: determining the risks of the multiple items based on product information, where the product information includes one or more of active ingredients, drug classifications, product classifications, and high-risk types.

[0055] In the process of determining the risks of multiple items, the risks of multiple items can be determined based on product information. Product information may include active ingredients P1, drug classification P2, product classification P3 and high-risk type P4, where drug classification can be divided into chemical preparations and traditional Chinese medicine, product classification can be divided into drugs, devices, vaccines and cosmetics, and high-risk types can be divided into injections, blood products, vaccines, psychotropic drugs and narcotic drugs.

[0056] After obtaining product information, you can first convert each product information into a corresponding value, then perform weighted summation on the product information to obtain a weighted product information index PI, and then determine the risks of multiple projects based on the product information index. The specific formula is as follows:

[0057]

[0058] In the formula, PI is the product information index, j is the serial number of the product information, P j is the jth product information, w Pj is the weighted coefficient of the j-th product information.

[0059] This embodiment uses product information as a reference factor for the project risk of the drug vigilance system, can systematically, scientifically, objectively, and multi-angle assess the risks of multiple projects, and can provide support and reference for the risk management of the drug vigilance system.

[0060] In one embodiment of the present application, determining the risks of multiple items of a drug vigilance system includes: determining the risks of multiple items based on adverse reaction information, where the adverse reaction information includes one or more of a monthly suspected serious report amount and a monthly serious adverse event report amount.

[0061] In the process of determining the risks of multiple projects, the risks of multiple projects can be determined based on adverse reaction information. The adverse reaction information can include monthly suspected serious reports SUSAR (Suspicious and Unexpected Serious Adverse Reactions) and monthly serious adverse event reports SAE (Serious Adverse Event).

[0062] After obtaining the adverse reaction information, the adverse reaction information can be weighted and summed to obtain a weighted adverse reaction information index, and then the risks of multiple projects can be determined based on the adverse reaction information index. The specific formula is as follows:

[0063] ARI=SUSAR×w SUSAR +SAE×w SAE

[0064] Where ARI is the adverse reaction information index, SUSAR is the monthly suspected serious report number, SAE is the monthly serious adverse event report number, w SUSAR is the weighting coefficient of the number of suspected serious reports per month, w SAE is the weighting factor for the monthly number of serious adverse event reports.

[0065] This embodiment uses adverse reaction information as a reference factor for the project risk of the pharmacovigilance system, can evaluate the project risk according to SUSAR and SAE, and provide support and reference for the risk management of the pharmacovigilance system.

[0066] Figure 2 A flowchart of a risk ranking method provided in another embodiment of the present application.

[0067] Step 210: Receive a risk ranking request input by a user in the pharmacovigilance system.

[0068] The risk ranking request includes the user's identification information, which is used to request the pharmacovigilance system to rank the risks of multiple projects based on the level information and the preset mapping relationship. The pharmacovigilance system can learn the level of the user who issued the risk ranking request based on the user's identification information, and make a ranking result for specific project risks based on the level and the preset mapping relationship.

[0069] Step 220: When a user accesses a risk display page in the pharmacovigilance system, the level information of the user of the pharmacovigilance system is obtained.

[0070] Specifically, when a user accesses the risk display page, the user's level information can be obtained, and the risks of multiple projects can be determined, so that when the user issues a risk ranking request, the drug vigilance system can quickly obtain the project risk ranking results based on the level information that has been obtained and the risks of the projects that have been determined. It is also possible that when a user accesses the risk display page, a risk ranking request is automatically issued, and the drug vigilance system quickly obtains the project risk ranking results based on the level information that has been obtained, the risks of the projects that have been determined, and the preset mapping relationship of the risk ranking. Since the purpose of users visiting the risk display page is usually to understand the risk situation of the project, directly displaying the project risk ranking results corresponding to the user's level when the user visits the risk display page is beneficial for users to obtain the project risk ranking results conveniently and quickly, further improving the user's experience.

[0071] Step 230: Determine the risks of multiple items of the pharmacovigilance system.

[0072] Specifically, when a user accesses the risk display page in the pharmacovigilance system, the risks of multiple items in the pharmacovigilance system can be determined. The risks of multiple items in the pharmacovigilance system can be determined based on enterprise information, product information, and adverse reaction information. Each enterprise information, product information, and adverse reaction information is converted into a corresponding numerical value, and then weighted summed to obtain the risk index of multiple items. The specific formula is as follows:

[0073] RI=EI×w EI +PI×w PI +ARI×w ARI

[0074] In the formula, RI is the risk index of the project, EI is the enterprise information index of the project, PI is the product information index, and ARI is the adverse reaction information index. For the description of the enterprise information index EI, the product information index PI and the adverse reaction information index ARI, please refer to the description in the above embodiment, which will not be repeated here. EI 、w PI 、w PIThey are the weighting coefficients of the enterprise information index EI, product information index PI and adverse reaction information index ARI. By assigning corresponding weights to each information index, the project's risk index RI is calculated.

[0075] Step 240: Based on the level information and the preset mapping relationship, the risks of multiple projects are sorted to obtain a project risk sorting result.

[0076] After calculating the risk index RI of the project, multiple project risks are sorted. Based on the level information and preset mapping relationship, users of different levels are sorted in a targeted manner. For example, for senior users, projects with higher risk index RI are displayed first, and for junior users, projects with lower risk index RI are displayed first, so that users can avoid difficulty in finding project risks suitable for them in a large number of projects, improve user work efficiency, and increase the convenience and efficiency of the drug vigilance system.

[0077] Step 250: Display the project risk ranking results to the user.

[0078] After obtaining the project risk ranking results, the corresponding project risk ranking results can be displayed or pushed to the user or the interface used by the user, so that the user can immediately see the ranking results and find project risks suitable for processing in the ranking results.

[0079] Figure 3 A schematic diagram of the structure of a risk ranking device provided in an embodiment of the present application includes:

[0080] The acquisition module 310 is used to obtain the level information of the user currently accessing the pharmacovigilance system and determine the risks of multiple projects in the pharmacovigilance system, wherein there is a preset mapping relationship between users of different levels and different project risk rankings in the pharmacovigilance system.

[0081] The sorting module 320 sorts the risks of multiple projects based on the level information and the preset mapping relationship to obtain a project risk sorting result.

[0082] The display module 330 is used to display the project risk ranking results to the user.

[0083] The risk ranking device of the present application can obtain the level information of users of the drug vigilance system, and perform corresponding risk ranking according to different level information, so that users of different levels can preferentially see the project risks that are suitable for them to handle.

[0084] According to an embodiment of the present application, before acquiring the level information of the user currently accessing the drug vigilance system, the acquisition module 310 also includes: receiving a risk ranking request input by the user in the drug vigilance system, the risk ranking request including the user's identification information, which is used to request the drug vigilance system to rank the risks of multiple projects based on the level information and a preset mapping relationship.

[0085] According to an embodiment of the present application, when a user accesses a risk display page in the pharmacovigilance system, the acquisition module 310 acquires the level information of the user currently accessing the pharmacovigilance system and determines the risks of multiple items of the pharmacovigilance system.

[0086] According to an embodiment of the present application, the acquisition module 310 includes: a preset mapping relationship between users of different levels and different project risk rankings is determined according to pharmacovigilance regulations, wherein the pharmacovigilance system is built according to the standard operating procedure document of pharmacovigilance.

[0087] According to an embodiment of the present application, the acquisition module 310 includes: the pharmacovigilance system periodically detects risks of multiple items in the pharmacovigilance system.

[0088] According to an embodiment of the present application, the acquisition module 310 acquires the identity of the user currently accessing the pharmacovigilance system; and determines the level information of the user according to the identity.

[0089] According to an embodiment of the present application, the acquisition module 310 determines the risks of multiple projects based on enterprise information, and the enterprise information includes one or more of enterprise classification, enterprise operation type, enterprise business type, enterprise product type, enterprise annual income, total number of enterprise employees and enterprise address.

[0090] According to an embodiment of the present application, the acquisition module 310 weights the enterprise information to obtain a weighted enterprise information index; and determines the risks of multiple projects based on the enterprise information index.

[0091] According to an embodiment of the present application, the acquisition module 310 determines the risks of multiple items based on product information, where the product information includes one or more of active ingredients, drug classification, product classification, and high-risk type.

[0092] According to an embodiment of the present application, the acquisition module 310 weights the product information to obtain a weighted product information index; and determines the risks of multiple projects based on the product information index.

[0093] According to an embodiment of the present application, the acquisition module 310 determines the risks of multiple projects based on adverse reaction information, where the adverse reaction information includes one or more of a monthly suspected serious report amount and a monthly serious adverse event report amount.

[0094] According to an embodiment of the present application, the acquisition module 310 weights the adverse reaction information to obtain a weighted adverse reaction information index; and determines the risks of multiple projects according to the adverse reaction information index.

[0095] For the specific definition of the risk ranking device, please refer to the definition of the risk ranking method above, which will not be repeated here.

[0096] Figure 3 FIG. 4 is a block diagram of an electronic device 400 for executing a risk ranking method provided by an exemplary embodiment of the present application, including a processor 410 and a memory 420 .

[0097] The memory 420 is used to store the processor executable instructions. The processor is used to run the executable instructions to execute the risk ranking method described in any one of the above embodiments.

[0098] The present application also provides a computer-readable storage medium, wherein the storage medium stores a computer program, and the computer program is used to execute the risk ranking method described in any one of the above embodiments.

[0099] The risk ranking method and device of the present application can obtain the level information of users of the drug vigilance system, and perform corresponding risk ranking according to different level information, so that users of different levels can preferentially see the project risks that are suitable for them to handle, thereby improving the work efficiency of users.

[0100] In the above embodiments, it can be implemented in whole or in part by software, hardware, firmware or any other combination. When implemented by software, it can be implemented in whole or in part in the form of a computer program product. The computer program product includes one or more computer instructions. When the computer program instructions are loaded and executed on a computer, the process or function described in the embodiment of the present invention is generated in whole or in part. The computer can be a general-purpose computer, a special-purpose computer, a computer network, or other programmable device. The computer instructions can be stored in a computer-readable storage medium, or transmitted from one computer-readable storage medium to another computer-readable storage medium. For example, the computer instructions can be transmitted from a website site, a computer, a server end or a data center by wired (e.g., coaxial cable, optical fiber, digital subscriber line (digital subscriber line, DSL)) or wireless (e.g., infrared, wireless, microwave, etc.) mode to another website site, computer, server end or data center. The computer-readable storage medium can be any available medium that can be accessed by a computer or a data storage device such as a server end, a data center, etc. that includes one or more available media integrated. The available medium may be a magnetic medium (eg, a floppy disk, a hard disk, a magnetic tape), an optical medium (eg, a digital video disc (DVD)), or a semiconductor medium (eg, a solid state disk (SSD)).

[0101] Those of ordinary skill in the art will appreciate that the units and algorithm steps of each example described in conjunction with the embodiments disclosed herein can be implemented in electronic hardware, or a combination of computer software and electronic hardware. Whether these functions are performed in hardware or software depends on the specific application and design constraints of the technical solution. Professional and technical personnel can use different methods to implement the described functions for each specific application, but such implementation should not be considered to be beyond the scope of this application.

[0102] In the several embodiments provided in the present application, it should be understood that the disclosed systems, devices and methods can be implemented in other ways. For example, the device embodiments described above are only schematic. For example, the division of the units is only a logical function division. There may be other division methods in actual implementation, such as multiple units or components can be combined or integrated into another system, or some features can be ignored or not executed. Another point is that the mutual coupling or direct coupling or communication connection shown or discussed can be through some interfaces, indirect coupling or communication connection of devices or units, which can be electrical, mechanical or other forms.

[0103] The units described as separate components may or may not be physically separated, and the components shown as units may or may not be physical units, that is, they may be located in one place or distributed on multiple network units. Some or all of the units may be selected according to actual needs to achieve the purpose of the solution of this embodiment.

[0104] In addition, each functional unit in each embodiment of the present application may be integrated into one processing unit, or each unit may exist physically separately, or two or more units may be integrated into one unit.

[0105] The above is only a specific implementation of the present application, but the protection scope of the present application is not limited thereto. Any person skilled in the art who is familiar with the present technical field can easily think of changes or substitutions within the technical scope disclosed in the present application, which should be included in the protection scope of the present application. Therefore, the protection scope of the present application should be based on the protection scope of the claims.

Claims

1. A risk ranking method, characterized in that: Applied in a pharmacovigilance system, the pharmacovigilance system is built according to the pharmacovigilance standard operating procedure document, and the sorting method includes: Acquiring level information of a user currently accessing the pharmacovigilance system, and determining risks of multiple projects in the pharmacovigilance system, wherein there is a preset mapping relationship between users of different levels and different project risk rankings in the pharmacovigilance system, and the preset mapping relationship between users of different levels and different project risk rankings is determined according to pharmacovigilance regulations; Based on the level information and the preset mapping relationship, the risks of the multiple projects are sorted to obtain a project risk sorting result, so that users of different levels can preferentially see the project risks that are suitable for them to handle; The project risk ranking results are displayed to the users, wherein the project risk ranking results for users of different levels are different.

2. The sorting method according to claim 1, characterized in that: Before obtaining the level information of the user currently accessing the pharmacovigilance system, the method further includes: A risk ranking request input by the user in the pharmacovigilance system is received, wherein the risk ranking request includes identification information of the user and is used to request the pharmacovigilance system to rank the risks of the multiple projects based on the level information and the preset mapping relationship.

3. The sorting method according to claim 1, characterized in that: The obtaining of level information of a user of the pharmacovigilance system and determining risks of multiple items of the pharmacovigilance system includes: When the user accesses the risk display page in the pharmacovigilance system, the level information of the user currently accessing the pharmacovigilance system is obtained, and the risks of multiple items of the pharmacovigilance system are determined.

4. The sorting method according to claim 1, characterized in that: The obtaining of level information of a user currently accessing the pharmacovigilance system includes: Obtaining the identity of the user currently accessing the pharmacovigilance system; According to the identity identifier, the level information of the user is determined.

5. The method according to claim 1, characterized in that: Determine the risks of multiple items of the pharmacovigilance system, including: The risks of the multiple projects are determined according to the adverse reaction information, wherein the adverse reaction information includes one or more of a monthly suspected serious report amount and a monthly serious adverse event report amount.

6. The method according to claim 5, characterized in that Determining the risks of the plurality of items according to the adverse reaction information includes: Weighting the adverse reaction information to obtain a weighted adverse reaction information index; The risks of the multiple items are determined according to the adverse reaction information index.

7. A risk ranking device, characterized in that: Applied in a pharmacovigilance system, the pharmacovigilance system is built according to the standard operating procedure document of pharmacovigilance, and the sorting device includes: an acquisition module, used to acquire level information of a user currently accessing the pharmacovigilance system, and determine the risks of multiple projects in the pharmacovigilance system, wherein there is a preset mapping relationship between users of different levels and different project risk rankings in the pharmacovigilance system, and the preset mapping relationship between users of different levels and different project risk rankings is determined according to pharmacovigilance regulations; A sorting module, used to sort the risks of the multiple projects based on the level information and the preset mapping relationship, and obtain a project risk sorting result, so that users of different levels can preferentially see the project risks that are suitable for them to handle; A display module is used to display the project risk ranking results to the user, wherein the project risk ranking results of users of different levels are different.

8. A computer-readable storage medium storing a computer program, wherein the computer program is used to execute the risk ranking method according to any one of claims 1 to 6.

9. An electronic device, comprising: processor; a memory for storing instructions executable by the processor, Wherein, the processor is used to execute the risk ranking method described in any one of claims 1 to 6 above.

Images